The data illustrates the value the top 10 medical technology venture financing rounds worldwide in 2017. In that year, Grail had a Series B venture round valued at 900 million USD.
Grail (Series B) | 900 |
Verily Life Sciences (Seed capital) | 800 |
Guardant Health (Series E) | 360 |
Annoroad (Undisclosed) | 105 |
Outset Medical (Series C) | 76.5 |
Neuropace (Undisclosed) | 74 |
Electrocore (Series B) | 70 |
Respicardia (Series F) | 58.5 |
Color Genomics (Series C) | 52 |
Moximed (Series C) | 50 |